Immuneering Corporation (BOATS:IMRX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of class A common stock or pre-funded warrants Announced: Leerink Partners +1 Dealers: Leerink Partners (co-lead), Oppenheimer & Co. Inc. (co-lead) Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes | Sep 24, 2025 |
| Private placement of class A common stock or non-voting Class B common stock Announced: US$25M · Leerink Partners +1 Dealers: Leerink Partners, Oppenheimer & Co. Inc. Buyers: Sanofi ($25.0 million of Class A common stock or non-voting Class B common stock) Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes | Sep 24, 2025 |
| Private placement of class A common stock (or pre-funded warrants) and accompanying purchase warrants Closed: US$25M raised · US$3.95 a share · Warrants at US$5.5 for 60 months · Leerink Partners Dealers: Leerink Partners Use of proceeds: Support development of atebimetinib, its Deep Cyclic Inhibitor of MEK, for cancer patients | Aug 26, 2025 |
| At-the-market programme of common stock Closed: US$13.7M raised | Jan 13, 2025 |